Skyline Diagnostics Preps Leukemia Test for US Launch; Gains CE-IVD Mark
March 15, 2011
Skyline Diagnostics Preps Leukemia Test for US Launch; Gains CE-IVD Mark
Skyline has received $1.5 million from the Dutch government to support a clinical study of AMLprofiler that will generate data it can use when it seeks US Food and Drug Administration clearance for the test next year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Skyline Dx Partners with LabPMM to Offer Array-based AML Testing Service in Europe
June 26, 2012 / BioArray News - After Decade as CRO, Shanghai Biochip Plans Move into Chinese Molecular Dx Market
December 18, 2012 / BioArray News - Team Uses Affy's OncoScan to Develop Prostate Cancer Prognostic Signature, Envisions Clinical Use
October 23, 2012 / BioArray News - Almac Dx Plans to Debut Array-based Colorectal Cancer-Recurrence Test Next Year
November 15, 2011 / BioArray News - Clavis Pharma Taps Skyline Dx for Array-based Patient Selection in AML Drug Trial
September 6, 2011 / BioArray News